Scientific Vita
Publi­cations
Con­tact

Prof. Dr.

Adelheid Cerwenka

Academic Education and University Degrees
2007
Venia Legendi for Immunology, University of Heidelberg, Faculty of Medicine, Heidelberg, Germany, mentor Prof. Stefan Meuer, Heidelberg, Germany
1991 - 1995
PhD, Institute of Immunology, University of Vienna, Austria, supervised by Prof. Walter Knapp
1986 - 1991
Diploma in Pharmacy, Institute of Immunology, University of Vienna, Austria

Employment
2017 - today
Full Professor of Immunbiochemistry, Heidelberg University, Medical Faculty Mannheim, Germany
2003 - 2017
Head of Boveri Junior Group “Innate Immunity” at the German Cancer Research Center, Heidelberg, Germany
2001 - 2003
Head of Laboratory, Division of Autoimmune Diseases, Novartis Research Institute, Vienna, Austria
1998 - 2001
Post-doc, DNAX Research Institute and University of California, San Francisco, USA, with Prof. Lewis L. Lanier
1996 -1998
Post-doc, University of California, San Diego, CA, USA and at the Trudeau Institute, NY, USA, with Prof. Richard W. Dutton
Stojanovic A, Cerwenka A. 2018. Checkpoint inhibition: NK cells enter the scene. Nat Immunol. 19(7):650-652.
Correia MP, Stojanovic A, Bauer K, Juraeva D, Tykocinski LO, Lorenz HM, Brors B, Cerwenka A. 2018. Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proc. Natl. Acad. Sci. (USA). 115(26):E5980-E5989.
Cerwenka A, Lanier LL. 2018. Natural killers join the fight against cancer. Science. 359(6383):1460-1461.
Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, Lasitschka F, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, Cerwenka A. 2018. Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis. J Hepatol. 68(3):421-430.
Cerwenka A, Lanier LL. 2016. NK cell memory in viral infection, inflammation and cancer, Nature Immunology Reviews. 16(2):112-23.
Rölle A, Pollmann J, Ewen EM, Le VT, Halenius A, Hengel H, Cerwenka A. 2014. IL-12 producing monocytes and HLA-E drive NKG2C+ NK cell expansion. J. Clin. Invest. 124(12):5305-16.
Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A. 2013. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood. 122(5):684-693.
Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. 2012. Sustained effector function of IL-12/15/18 preactivated NK cells against established tumors. J Exp Med. 209(13):2351-65.
Cerwenka A, Baron JL, and Lanier LL. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits NK cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. (USA). 98(20):11521-6.
Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 12(6): 721-727.
Address
Office: Tridomus, Haus C, Ebene 5
Ludolf-Krehl-Strasse 13 - 17
Lab: Tridomus, Haus B, Ebene 3
Ludolf-Krehl-Strasse 7 - 11
D-68167 Mannheim
eMail
Adelheid.Cerwenka@medma.uni-heidelberg.de